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Background: Severe hypoglycaemia still represents a significant problem in insulin-treated diabetes. Most patients
do not experience severe hypoglycaemia often. However, 20% of patients with type 1 diabetes experience
recurrent severe hypoglycaemia corresponding to at least two episodes per year. The effect of insulin analogues on
glycaemic control has been documented in large trials, while their effect on the frequency of severe hypoglycaemia
is less clear, especially in patients with recurrent severe hypoglycaemia. The HypoAna Trial is designed to
investigate whether short-acting and long-acting insulin analogues in comparison with human insulin are superior
in reducing the occurrence of severe hypoglycaemic episodes in patients with recurrent hypoglycaemia. This paper
reports the study design of the HypoAna Trial.
Methods/design: The study is a Danish two-year investigator-initiated, prospective, randomised, open, blinded
endpoint (PROBE), multicentre, cross-over trial investigating the effect of insulin analogues versus human insulin on
the frequency of severe hypoglycaemia in subjects with type 1 diabetes. Patients are randomised to treatment with
basal-bolus therapy with insulin detemir / insulin aspart or human NPH insulin / human regular insulin in random
order. The major inclusion criterion is history of two or more episodes of severe hypoglycaemia in the preceding
year.
Discussion: In contrast to almost all other studies in this field the HypoAna Trial includes only patients with major
problems with hypoglycaemia. The HypoAna Trial will elucidate whether basal-bolus regimen with short-acting and
long-acting insulin analogues in comparison with human insulin are superior in reducing occurrence of severe
hypoglycaemic episodes in hypoglycaemia prone patients with type 1 diabetes. www.clinicaltrials.gov:
NCT00346996.
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Severe hypoglycaemia still represents a significant risk for
many patients with type 1 diabetes. The condition is
feared by patients [1,2] and relatives [3] and remains a
major barrier in achieving recommended glycaemic tar-
gets [4]. Moreover, severe hypoglycaemia may, although
rarely, lead to permanent brain damage or death [5]. The
frequency of severe hypoglycaemia in type 1 diabetic
populations is 1–1.7 episodes per patient-year [6-14]. The
distribution of episodes is, however, very skewed. Thus,
20% of patients with type 1 diabetes experience two or
more episodes of severe hypoglycaemia per year [15].
Once prone to recurrent severe hypoglycaemia, patients
often remain so throughout their life.
Insulin analogues were developed to improve treat-
ment of insulin-treated diabetes with respect to glycae-
mic control and avoidance of hypoglycaemic episodes.
Short-acting insulin analogues (aspart, lispro and gluli-
sine) were designed to mimic the fast physiological
postprandial insulin release and long-acting insulin ana-
logues (detemir and glargine) were designed to mimic
the basal continuous insulin release with minimal peak
action, thereby leading to a presumed decreased risk of
hypoglycaemia. The effect of insulin analogues on gly-
caemic control has been documented in large trials
[16,17]. However, for several reasons the impact of insu-
lin analogues on the frequency of severe hypoglycaemia
is less clear. Firstly, most studies comparing the effects
of human insulin with those of insulin analogues specif-
ically exclude patients at risk of severe hypoglycaemia,
such as patients with previous severe events or impaired
hypoglycaemia awareness, from participation [18-21].
This renders the trials insufficiently statistically powered
to detect differences in the frequency of severe
hypoglycaemia and the conclusions from these studies
can not readily be extrapolated to patient groups prone
to severe hypoglycaemia. Secondly, hypoglycaemia is
often less well defined and detected, at best as a second-
ary endpoint, with reports including a mixture of mild,
severe, and asymptomatic hypoglycaemia. Thirdly, severe
hypoglycaemia should be analysed according to a statis-
tic model that takes into account the much skewed
distribution of episodes e.g. negative binomial or zero-
inflated models [22].
A Cochrane review comparing short-acting insulin ana-
logues with human insulin included 49 studies, of which
10 studies were eligible in relation to hypoglycaemia [16].
The analysis showed that the overall mean occurrence of
hypoglycaemic episodes was lower for short-acting analo-
gues in comparison to regular insulin in patients with type
1 diabetes (−0.2 per patient per month (95% confidence
interval: -1.1 to 0.7)). No statistical comparative calcula-
tions were possible specifically addressing severe hypo-
glycaemia due to inconsistent and bias-prone definitionsin the different studies. However, in the analogue group
the incidence of severe hypoglycaemia ranged from 0–247
(median 22) episodes per 100 patient-year compared to
the incidence in the human insulin group ranging from 0–
544 (median 46).
After the initiation of the present study, a meta-
analysis based on 20 studies (duration > 12 weeks) was
published comparing long-acting insulin analogues with
long-acting human insulin in type 1 diabetes, including
12, 15 and 13 studies analysing any hypoglycaemia, se-
vere hypoglycaemia, and nocturnal hypoglycaemia, re-
spectively [17]. The analysis showed that long-acting
analogues are not associated with a significant reduction
of overall risk of any hypoglycaemia in comparison with
NPH insulin. When episodes of severe hypoglycaemia
and nocturnal hypoglycaemia were separately analysed,
insulin detemir, but not insulin glargine, was associated
with a reduced risk compared to human NPH insulin
(OR 0.73 (0.60 - 0.89), p = 0.002 and OR 0.69 (0.55 -
0.86), p = 0.001; respectively). There are important lim-
itations with the meta-analysis. Firstly, the trials use
different criteria for hypoglycaemia, different methods in
recording severe hypoglycaemia, and many trials are not
randomised. Secondly, the participants in the studies are
relatively young (mean: 34 years) with a short duration
of diabetes (mean: 13 years) suggesting that the partici-
pants’ state of hypoglycaemia awareness is relatively un-
affected. Thirdly, in some trials the number of insulin
injections per day are different in the human insulin
group and the insulin analogue group. Finally, the vast
majority of the trials in the analysis were sponsored by
manufacturers of long-acting insulin analogues. To our
knowledge a direct comparison of long acting insulin
analogues and long-acting human insulin has not been
made in patients at high risk of severe hypoglycaemia.
When it comes to patients at high risk of severe
hypoglycaemia, who may have the greatest potential
benefit from insulin analogue therapy, there is only one
small, randomised,12-month cross-over study comparing
the effect of the short-acting insulin analogue (lispro)
and regular human insulin on the frequency of severe
hypoglycaemia [23]. The study population comprised 33
patients with type 1 diabetes and hypoglycaemia un-
awareness. There was a trend towards a lower incidence
of severe hypoglycaemia during treatment with insulin
lispro in comparison with human insulin (p = 0.087). An-
other study in 322 women with type 1 diabetes, who
were pregnant or planning pregnancy and therefore
being at relatively high risk of severe hypoglycaemia due
to very tight glycaemic control, compared insulin aspart
with human insulin as meal-time insulin (with human
NPH insulin as basal insulin) using an open-label, ran-
domised, parallel-group, multicentre design. Although
the risk of severe hypoglycaemia in women treated with
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Figure 1 Graphic presentation of the HypoAna study which is a
prospective randomised cross-over study of the effect of
insulin analogues and human insulin on the frequency of
severe hypoglycaemia in patients with type 1 diabetes and
recurrent hypoglycaemia.
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reach statistical significance [24]. In a randomised 24-
week pilot study of 15 patients with type 1 diabetes
complicated by severe hypoglycaemia, comparing rigor-
ous hypoglycaemia avoidance with insulin analogue ther-
apy (lispro and glargine), continuous subcutaneous
insulin therapy (CSII) or education alone (but not in-
cluding any control group), hypoglycaemia awareness
was restored and further severe hypoglycaemia was pre-
vented with concomitant improvement in glycaemic
control in the analogue and CSII groups [25].
The HypoAna Trial is designed to elucidate whether
short-acting and long-acting insulin analogues (insulin
aspart and insulin detemir) in comparison with human
regular and NPH insulin are superior with respect to re-
ducing the occurrence of severe hypoglycaemic episodes
in patients with recurrent hypoglycaemia. There is an
urgent need for this evidence in clinical practice and a
need to elucidate if the higher costs of insulin analogues
are justified in this respect. However, since the structures
of different insulin analogues are not similar, the results
of this study cannot be directly extrapolated to other in-
sulin analogues (lispro, glulisine and glargine).
Objective
The primary objective is to evaluate the effect of treat-
ment with insulin analogue and human insulin over the
preceding 9 months in each treatment arm on the inci-
dence of severe hypoglycaemia in patients with type 1
diabetes prone to hypoglycaemia.
The secondary objectives are – with reference to the
ADA criteria for classification of hypoglycaemia [26] –
to evaluate the effects of insulin analogue and human in-
sulin from 3 to 12 months of treatment on the incidence
of:
 documented (mild) symptomatic hypoglycaemia.
 asymptomatic hypoglycaemia.
 severe hypoglycaemia, documented symptomatic
hypoglycaemia, and asymptomatic hypoglycaemia
during daytime.
 severe hypoglycaemia, documented symptomatic
hypoglycaemia, and asymptomatic hypoglycaemia
during night-time
Methods/design
Design
The study is a Danish two-year, investigator-initiated,
prospective, randomised, open, blinded endpoint
(PROBE), multicentre, cross-over trial investigating the
effect of insulin analogues versus human insulin on the
frequency of severe hypoglycaemia (Figure 1). Patients
are randomised to treatment with basal-bolus therapy
with insulin detemir and insulin aspart (LevemirW/NovorapidW) or human NPH insulin and human regular
insulin (InsulatardW/ActrapidW), in random order. Doses
of insulin are adjusted according to individual patient
need at the discretion of the investigator. Thus, a treat-
to-target design is deliberately not used in order not to
intervene with present glycaemic control and everyday
clinical practice, which otherwise in itself will interfere
with the risk of hypoglycaemia. The best obtainable gly-
caemic control for the individual patient is strived for in
both treatment periods. The protocol did not specify the
timing and number of insulin injections per day. In gen-
eral, a four times daily basal-bolus regimen was selected,
e.g. basal insulin before bedtime and prandial insulin be-
fore meals. Patients were instructed in insulin injection
technique at the beginning of each treatment arm. End-
points are assessed during the last 9 months of each
treatment arm, the first 3 months being used for run-in
on a new treatment regimen. Optional admissions for
overnight plasma glucose measurements followed by
three days of blinded continuous glucose monitoring
(CGM) are performed after 6 and 12 months of treat-
ment in each treatment arm.
Subjects
From November 2006 to June 2007 questionnaires were
sent to 6112 patients with type 1 diabetes attending the
outpatient clinics at Steno Diabetes Center, Hillerød
Hospital, Hvidovre Hospital, Bispebjerg Hospital, Odense
University Hospital, Copenhagen University Hospital
(Rigshospitalet), and Aarhus University Hospital. From
some centres reminders were sent once. A total of 3861
patients filled in the questionnaire (63.2%). Patients were,
among other things, asked how many episodes of severe
hypoglycaemia they had experienced during the last year.
Patients with two or more episodes were identified
(n = 720) and invited by letter to participate in the
HypoAna Trial. Subjects were included in the HypoAna
Trial from May 2007 to November 2009. The inclusion
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or more episodes of severe hypoglycaemia in the previous
year (defined as need for third party assistance to restore
blood glucose level), age > 18 years, and a negative preg-
nancy test. There were no inclusion criteria regarding the
pre-randomisation insulin treatment. Exclusion criteria
are treated adrenal or growth hormone insufficiency or
untreated hypothyroidism, myocardial infarction or cor-
onary revascularisation, transient ischemic attack or
stroke within the last three months, history of malig-
nancy unless a disease-free period exceeding five years,
history of alcohol or drug abuse, pregnancy or lactation,
and women of childbearing potential who are not using
chemical or mechanical contraception. Criteria for dis-
continuation are voluntary withdrawal of consent, preg-
nancy, or non-compliance with the study protocol as
judged by the investigator. Discontinuing patients are not
substituted, but data on discontinuing patients are
included in data analyses on an intention-to-treat basis.
The study was approved by The Regional Committee on
Biomedical Research Ethics (# H-KA-20070008) and the
Danish Medicines Agency (# 2612–3397). The study is
registered at www.clinicaltrials.gov (# NCT00346996).
The Study will be conducted in accordance with the Hel-
sinki Declaration.
Experimental protocol
Participants attend the outpatient clinics every three
months. After informed consent the participants meet
fasting at the first visit in the outpatient clinic at 08:00 a.
m. Information about demography, lifestyle and clinical
characteristics are gathered. Weight and height are mea-
sured without shoes. Blood pressure is measured twice
after 10 minutes rest in a sitting position. As a measure
of peripheral and autonomic neuropathy, biothesiome-
try, beat-to-beat variation, and orthostatic blood pres-
sure responses are assessed. A 12-lead electrocardiogram
is recorded and visually assessed. State of hypoglycaemia
awareness is classified by a validated method [27,28].
Patients are asked: “Do you have symptoms when you
have a hypo?” The subjects can answer “always” (normal
awareness), “usually” (impaired awareness), and “occa-
sionally” or “never” (unawareness). The frequencies of
episodes of mild hypoglycaemia per week (defined as
manageable by the patient) and severe hypoglycaemia in
the previous year are determined on the basis of the
aforementioned questionnaires used for screening of
patients for the present trial. Recall of severe hypo-
glycaemia is well preserved during a one-year period
[27]. Fasting blood samples are taken and samples for
later analyses are centrifuged, processed and stored im-
mediately at −80°C. HbA1c and C-peptide concentra-
tions are measured centrally at Steno Diabetes Center.
At the end of visit 1 a 30-min ACTH test (SynacthenW,0.25 mg i.v.) is performed. After a breakfast in the out-
patient clinic the patient’s insulin injection technique is
tested and corrected if needed. Three questionnaires
about quality of life are filled in. The EuroQol-5 dimen-
sion quality of life index (EQ-5D), the Insulin Treatment
Satisfaction Questionnaire (ITSQ) and the Hypoglycemia
Fear Survey (HFS). EQ-5D is a commonly used, short
questionnaire assessing health-related quality of life.
Patients describe their health status on five domains
(mobility, self-care, usual activities, pain/discomfort,
anxiety/depression) with three different answers: “I have
no problem”, “some problem”, or “extreme problem”.
Furthermore, patients rate health state on a visual
analogue scale [29,30]. The ITSQ measures treatment
satisfaction concerning the insulin regimen and com-
prises 22 questions about different aspects of insulin
treatment [31]. The HFS comprises 33 questions and
measures to what degree patients change daily practise
to avoid hypoglycaemia and measures different aspects
of worries of episodes of hypoglycaemia [32]. At the end
of the visit patients are centrally randomised at Steno
Diabetes Center by an assistant not further involved in
the trial, based on site-specific computer-generated ran-
domisation lists in blocks of four patients. Finally, free
study medication is handed out.
Endpoint registration
Severe hypoglycaemia
In case of a suspected episode of severe hypoglycaemia,
patients are instructed to make a telephone call within
24 hours to a call center served by a trained diabetes
nurse. The nurse performs a structured interview with
the patient to validate the severity (need for assistance
from others) and the plausibility of the event according
to Whipple’s triad: I) characteristic hypoglycaemic symp-
toms; II) biochemical confirmation with plasma
glucose ≤ 3.9 mmol/l; and III) adequate response to
treatment with carbohydrates, glucose or glucagon.
According to Whipple’s triad only episodes fulfilling all
criteria can be considered definite, whereas those fulfill-
ing two criteria can only be considered probable. Ques-
tions about time, place, blood glucose, possible cause(s)
of hypoglycaemia, and types of help given to the patient
are asked along with questions about health-related
quality of life and questions about any consequences of
the episode regarding physical or material damage and
work-related absenteeism. Furthermore, at every visit to
the outpatient clinic patients are asked if they have
experienced any episodes of severe hypoglycaemia not
recorded by telephone interview. In such cases an inter-
view is carried out by the patient’s doctor or nurse using
the same questionnaire as mentioned above. All tele-
phone interviews are done by the same two study nurses
(blinded to the treatment modality) located at Hillerød
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arm will be used for endpoint analyses.
Mild symptomatic and asymptomatic hypoglycaemia
Patients are instructed and strongly encouraged to make
a 7-point self-monitored blood glucose (SMBG) profile
two days a week in the entire study period. All values are
entered into a diary with study-specific guidance and at
every outpatient visit the diary is evaluated by the investi-
gator and copies of the relevant pages are saved as source
data. If patients measure a SMBG value ≤ 3.9 mmol/l,
they are instructed to write down if they have conco-
mitant symptoms of hypoglycaemia. All SMBG values
are measured with the AscensiaW CONTOURW blood
glucose monitoring system (Bayer Health Care, Leverku-
sen, Germany).
Nocturnal hypoglycaemia
Patients are instructed to measure a nocturnal blood
glucose once every month at 3 a.m. Moreover, patients
are invited (optional) to stay overnight at Steno Diabetes
Center four times during the study (two times at month
6 and 12 in every treatment arm). In the evening before
bedtime, a study-specific blinded continuous glucose
monitoring (CGM) device (GuardianW REAL-time (with
a “black” display), Medtronic Minimed, Northridge,
USA) is mounted by a trained study nurse and the pa-
tient is instructed how to calibrate the device, using ca-
pillary glucose measurements. Thereafter, a venous line
is inserted in an anticubital vein. During the night,
blinded samples for subsequent plasma glucose mea-
surements are drawn once every hour, while the patient
is sleeping.
CGM
Interstitial glucose concentrations are assessed for three
days in patients who accept the four optional overnight
stays at Steno Diabetes Center, i.e. 12 days of CGM in
total. After the three days the glucose sensor and moni-
tor are collected and data are downloaded to a computer
for further analysis. These data remain blinded until the
end of the study and are not used to control glycaemic
levels during the study period. Special blinded versions
of the CGM device with a “black screen” were supplied
by the manufacturer. The CGM data will provide a
unique possibility to assess the accuracy of CGM and
compare time spent at hypoglycaemia, number of
unrecognized episodes of hypoglycemia in this selected
patient population.
HbA1c and plasma glucose
At every visit to the outpatient clinic (totalling 9 visits per
patient) blood samples are drawn to measure HbA1clevels (analysed centrally at Steno Diabetes Center) and
random plasma glucose concentrations (measured locally).
Power calculation
In the power calculation, the number of events in each
treatment period is assumed to be distributed according
to a Poisson model. No period effect exceeding the
3 months of run-in is assumed. Based on the total num-
ber of observed events for each individual patient, the
number of events for a treatment period is reduced to a
binomial distribution:
Binomial (total number of events, λhuman insulin/(λhuman
insulin + λinsulin analogue)), which under the null hypothesis
of no difference in event rate between insulin analogues
and human insulin becomes binomial (total number of
events, ½). The power calculations are thus performed
with the use of an exact test of number of events in a bi-
nomial distribution with the probability of p = 1/2 versus
alternatively with the probability of P = λhuman insulin/(λhu-
man insulin + λinsulin analogue) = 1/(1+ λinsulin analogue/λhuman
insulin). The sample size calculation thus indicates the
total number of events needed. The study population is
selected to be patients with an expected increased risk
of severe hypoglycaemia. Assuming an incidence of 2.8
severe hypoglycaemic events per patient-year, corre-
sponding to 2.09 per 9 months treatment period, and
setting minimal relevant difference (MIREDIF) to a re-
duction in the incidence of severe hypoglycaemia of 15%
(based on the conclusion of the American Diabetes As-
sociation Workgroup on Hypoglycemia ”that any signifi-
cant reduction in severe hypoglycemia (that requiring
the assistance of another individual), even by as little as
10–20%, would be advantageous” [26]), this will corres-
pond to a reduction in the relation between human and
analogue insulin of: λinsulin analogue/λhuman insulin =
0.85. Setting power to 80% and a test level of 5%, the
total number of events needs to be 1220. With an
expected number of events of 2.09 + 1.75 (1.75 = 2.09 x
15% reduction in incidence of severe hypoglycaemia) =
3.84 events per 18 months’ treatment, this corresponds
to a need for 315 patients. With an expected dropout
rate of 15%, 370 patients need to be included.
Statistics
The crossover design makes it possible to compare the
two treatment modalities within the same person,
thereby minimising between-patient variation. This de-
sign is appropriate because type 1 diabetes is a chronic,
stable disease with slow progression. Therefore, the sta-
tus of the patient in the first treatment period is
assumed to be the same in the second period. To avoid
a possible period effect and unwelcome fluctuations in
blood glucose in relation to shift from one treatment
modality to the next, registration of the primary
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The long participation of two years per patient ensures a
sufficient time of observation to minimise the risk of
dealing with patients at particularly good or bad periods
of their illness. Therefore, the analysis will be based on
data from patients who complete the first treatment
period and at least 6 months of the second treatment
period. An analysis in a negative binomial distribution
or Poisson model will be used to describe the number
of events through a log link function as a linear function
of treatment, treatment period, HbA1c levels and other
relevant variables (state of hypoglycaemia awareness,
C-peptide status, age, duration of diabetes, daily insulin
dose). Individual differences in the observation period
will be adjusted for in the analysis.
Timeline
“Last patient, last visit” was November 2011.
Laboratory analysis
At the first visit fasting C-peptide, haemoglobin, haem-
atocrit, plasma creatinine, plasma sodium, and plasma
potassium, thrombocyte count, white blood cell count,
alanine aminotransferase, alkaline phosphatase, bilirubin,
total cholesterol, high and low density lipoprotein cho-
lesterols, triglycerides, thyroid-stimulating hormone
TSH, T4 and T3 are measured. These analyses are
repeated after 1 year (before changing insulin regimen)
and after 2 years (final visit). Participants with C-peptide
concentrations below 300 pmol/l or stimulated (venous
blood glucose concentration >12 mmol/l) C-peptide
concentrations below 600 pmol/l were considered C-
peptide negative. At every visit HbA1c and random
plasma glucose are measured. Biobank samples (serum,
plasma and DNA) are gathered at baseline and six times
(three times in each insulin regimen) during the study.
Urinary sodium and albumin concentration are deter-
mined in urine samples collected from two separate
nights at baseline and repeated after 1 year (before shift-
ing insulin regimen) and after 2 years (final visit). HbA1c
is measured centrally at Steno Diabetes Center using
High Performance Liquid Chromatography method on a
Tosoh Automated Glycohemoglobin Analyzer. C-peptide
is measured with an AutoDELFIA C-peptide kit (detec-
tion limit 5 pmol/l). An ACTH stimulation test was
undertaken at the first visit. All other analyses are per-
formed locally by routine methods.
Discussion
In contrast to almost all other studies in this field the
HypoAna Trial includes only patients with major
hypoglycaemic problems. The HypoAna Trial will eluci-
date whether short-acting and long-acting insulin analo-
gues in comparison with human insulin are advantageousin reducing the number of hypoglycaemic episodes in
these patients. If proven, this is of major importance to
the patients and their health care professionals in planning
optimal insulin regimens, and for the society from a cost-
benefit point of view because costs are substantially higher
for insulin analogues than for human insulin.
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